Identification of anti-CD16a single domain antibodies and their application in bispecific antibodies.

Identification of anti-CD16a single domain antibodies and their application in bispecific antibodies.
Cancer Biol Ther. 2019 Sep 29;:1-9
Authors: Zhao Y, Li Y, Wu X, Li L, Liu J, Wang Y, Liu Y, Li Q, Wang Z
Abstract
CD16a (FcγRIIIa) mediates the antibody dependent cellular cytotoxicity (ADCC) and is important for anti-tumor activities of many therapeutic antibodies. Bispecific antibody targeting natural killer (NK) cells has been studied for cancer therapy. In this work, anti-CD16a single-domain antibodies were identified from hCD16a immunized camel. Bispecific antibodies are then constructed by fusing these single domain antibodies with an anti-CEA single domain antibody. These bispecific antibodies can recruite NK cells to kill CEA-positive tumor cells, and inhibit tumor growth in vivo, suggesting that these anti-CD16a single domain antibodies are powerful tools to engaging NK cells for cancer therapy.
PMID: 31564196 [PubMed - as supplied by publisher]

Source: Cancer Biology and Therapy - September 28, 2019 Category: Cancer & Oncology Authors: Zhao Y, Li Y, Wu X, Li L, Liu J, Wang Y, Liu Y, Li Q, Wang Z Tags: Cancer Biol Ther Source Type: research